Analyst Ratings For Catalyst Biosciences (NASDAQ:CBIO)
Today, Chardan Capital raised its price target on Catalyst Biosciences (NASDAQ:CBIO) to $75.00 per share.
Some recent analyst ratings include
- 2/1/2018-B. Riley Reiterated Rating of Buy.
- 6/6/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 10/6/2016-HC Wainwright Reiterated Rating of Buy.
- 6/30/2016-Rodman & Renshaw initiated coverage with a Buy rating.
Recent Insider Trading Activity For Catalyst Biosciences (NASDAQ:CBIO)
Catalyst Biosciences (NASDAQ:CBIO) has insider ownership of 5.00% and institutional ownership of 22.89%.
- On 12/17/2015 Fletcher Payne, CFO, bought 10,000 with an average share price of $2.00 per share and the total transaction amounting to $20,000.00.
- On 12/17/2015 Nassim Usman, CEO, bought 4,000 with an average share price of $2.00 per share and the total transaction amounting to $8,000.00.
- On 12/17/2015 Stephen A Hill, Director, bought 5,000 with an average share price of $2.03 per share and the total transaction amounting to $10,150.00.
- On 12/5/2013 Scott Sandell, major shareholder, sold 1,000 with an average share price of $5.13 per share and the total transaction amounting to $5,130.00.
- On 11/21/2013 M James Barrett, major shareholder, sold 5,333 with an average share price of $5.16 per share and the total transaction amounting to $27,518.28.
- On 5/10/2013 Julia R Brown, Director, bought 6,000 with an average share price of $5.09 per share and the total transaction amounting to $30,540.00.
- On 3/11/2013 Stephen A Hill, CEO, bought 20,000 with an average share price of $4.43 per share and the total transaction amounting to $88,600.00.
Recent Trading Activity for Catalyst Biosciences (NASDAQ:CBIO)
Shares of Catalyst Biosciences closed the previous trading session at 26.53 down -0.75 2.75% with 22.510000228881836 shares trading hands.